Intraventricular Drug Delivery
Intraventricular Drug Delivery - Related Videos
14:55
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
0 Views •
Cited by 172 •
2013
We describe a method to target drugs to the central nervous system by either implanting a catheter or performing a bolus injection into the right lateral ventricle in mice. We focus specifically on the delivery of antisense oligonucleotides. This technique is readily adaptable to other drugs and to rats.
04:51
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
0 Views •
2025
This video demonstrates a method to generate a rat model of neonatal intraventricular hemorrhage. In this procedure, an anesthetized rat pup is injected with hemoglobin into the lateral ventricle of the brain. The hemoglobin causes oxidative stress and releases heme, simulating intraventricular hemorrhage. The resulting damage to brain tissues, driven by reactive oxygen species and inflammatory cytokines, leads to ventricular enlargement, a common consequence of intraventricular hemorrhage.
02:37
Ophthalmic Drug Delivery for Noninvasive Neuromodulation in a Mouse Model
0 Views •
2025
Source: Zhan, J., et al. Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity. J. Vis. Exp. (2019)This video demonstrates a non-invasive ophthalmic drug delivery method for targeted neuromodulation. The drug is delivered via eye drops, absorbed into the circulation, crosses the blood-brain barrier, and activates specific neuronal receptors.
05:53
Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
0 Views •
Cited by 5 •
2016
After puncturing the aorta through the inferior vena cava (IVC) to create an aorto-caval fistula in the mouse, solution containing a drug is infused into the IVC via the same needle, followed by incubation. This method enables more robust drug delivery to the venous endothelium compared to the external route.
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
0 Views •
Cited by 49 •
2016
Nanoparticles are emerging as promising drug delivery systems for a broad range of indications. Here, we describe a simple yet powerful method to manufacture silk nanoparticles using reverse engineered Bombyx mori silk. These silk nanoparticles can be readily loaded with a therapeutic payload and subsequently explored for drug delivery applications.
FAQs
Drug properties help determine how an agent behaves after reaching the cerebrospinal fluid. They can affect local availability, distribution through the central nervous system, and the extent to which neurological tissues are exposed. Pharmacology studies therefore consider these properties alongside the delivery site and dose when evaluating whether direct ventricular administration can produce useful brain exposure.
The administration site and movement of cerebrospinal fluid influence where the drug travels after placement in the ventricular system. These factors can change distribution within the central nervous system and the amount of drug reaching particular neurological tissues. Consequently, identical agents or doses may produce different exposure patterns when delivery conditions differ.
Bypassing the blood-brain barrier can increase local availability when systemic administration produces inadequate brain exposure. However, improved access does not automatically ensure safe or effective treatment. Outcomes still depend on the drug, dose, delivery site, and cerebrospinal fluid dynamics, so pharmacological evaluation must consider both the potential exposure benefit and factors that may limit performance.
The approach may use a catheter, a reservoir, or an injection into a ventricle to place the medication in or near the cerebrospinal fluid. These options provide different ways to achieve ventricular access for pharmacology studies. Selection of the access method is relevant because the delivery site and dosing conditions can influence subsequent drug distribution.
Researchers may consider intraventricular administration when systemic dosing does not provide adequate exposure in the brain. It supports studies of drug distribution, local availability, and treatment evaluation within the central nervous system. The method is therefore relevant when investigators need to examine how a therapeutic agent reaches neurological tissues under conditions that systemic delivery may not achieve.
Studies can evaluate how medication distributes through cerebrospinal fluid, whether neurological tissues receive increased local availability, and how effectively a treatment reaches the central nervous system. They can also examine how dose, drug properties, delivery site, and fluid dynamics affect results. Together, these measurements help relate administration conditions to therapeutic exposure, safety, and effectiveness.